tbuckley/cabot-search huggingface dataset:
Clinical Connections
Journal: Arthritis & Rheumatology (2019)

Vasculopathy precedes the onset of fibrosis in systemic sclerosis (SSc) and may be a primary event in the pathogenesis of SSc.The serum and dermal expression of milk fat globuleassociated protein with epidermal growth factor-and factor VIII-like domains (MFG-E8) is reduced in SSc patients.MFG-E8 inhibits latent transforming growth factor β (TGFβ)-induced expression of type I collagen, α-smooth muscle actin (α-SMA), and CCN2 by the interaction with the RGD domain of αv integrin in fibroblasts.Fujiwara et al found that in bleomycininduced fibrosis and TSK mouse models of SSc, deficient expression of MFG-E8 enhanced both pulmonary and skin fibrosis, and administration of recombinant MFG-E8 (rMFG-E8) significantly inhibited dermal fibrosis.These results suggest that vasculopathy-induced dysfunction of pericytes and endothelial cells (ECs), the main secretory cells of MFG-E8, may be associated with the decreased expression of MFG-E8 in SSc and may contribute to the pathogenesis of SSc.Integrin-modulating therapy, such as the administration of rMFG-E8, could hold promise for the treatment of fibrosis in SSc.
INFANT FEEDING
Authors: CLIFFORD G. GRULEE
Journal: JAMA (1926)

There is no question but that the laity is demanding of the general practitioner a more definite and extended knowledge of infant feeding than he is able to supply at the present time. My object in this paper is to decide whether such bewilderment as at present exists in the minds of the profession is justifiable from the standpoint of facts. In other words, is not every practitioner equipped to feed babies properly if he will use the means at his disposal, and a fair amount of common sense? What have we, as pediatricians, done to help him in this matter, and how far have the publications of men eminent in the profession gone toward increasing rather than reducing this bewilderment? If one takes up a pediatric journal of the last ten years and looks at the articles on infant feeding one will certainly be impressed, not by the simplicity,
Leads from the MMWR. Recommendations for preventing transmission of infection with HTLV-III/LAV in the workplace
Journal: JAMA (1985)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Water Hemlock Poisoning—Maine, 1992
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The treatment of Paget's disease of bone. Hobson's choice?
Journal: JAMA (1969)

Dr. David Hirschfeld, Junior Assistant Resident in Medicine, Jewish Hospital of St. Louis; and Assistant in Medicine, Washington University School of Medicine: A 62-year-old white woman was referred to this hospital in October 1968 for evaluation of Paget's disease, which was initially diagnosed by x-ray film in 1961 during intravenous pyelographic studies. The patient remained asymptomatic until 1963 when pain in the left side of the pelvis and left upper leg was noted. These symptoms have persisted with variable intensity to the present time. In 1967 the patient was subsequently seen at another institution and on two occasions received intravenously administered radioactive phosphorus therapy (sodium phosphate P32) for the complaints. In each instance, the administration of the isotope was apparently associated with symptomatic improvement of the bone pain. The patient denied any history of bone fracture or renal calculi. Physical examination revealed a middle-aged woman in no acute distress. Pulse
Outpatient needle localization and biopsy for nonpalpable breast lesions
Authors: M. J. Homer
Journal: JAMA (1984)

We reviewed 101 consecutive biopsy specimens of nonpalpable breast lesions obtained by needle localization. Forty-six biopsies were done on outpatients under local anesthesia and 16 more on inpatients under local anesthesia. The remaining 39 biopsies were performed on inpatients under general anesthesia. The complications and accuracy of the outpatient procedure were acceptable and comparable to those of the inpatient procedure. In our institution, there is almost a fivefold cost increase for the performance of this procedure under general anesthesia as an inpatient. We recommend that surgeons and radiologists work together to perfect preoperative localization techniques, and we strongly support the concept that this procedure should be performed on outpatients under local anesthesia for the majority of patients with nonpalpable mammographic abnormalities. (<i>JAMA</i>1984;252:2452-2454)
Correction:<i>Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism</i>
Journal: Annals of the Rheumatic Diseases (2019)

The specificity of the human monoclonal antibodies B02 and D10 used in functional experiments in this article, originally described as high affinity ACPAs, has been re-evaluated.In accordance with data that were made available to us (Ge et al., Arthritis Rheumatol, 2019; 71:210-221, and others), the two monoclonal antibodies used lack specific binding to citrullinated peptides in surface plasmon resonance (SPR) and other assays as described in the retraction note to Journal of Experimental Medicine (Amara et al Retraction J. Exp Med 2019; 216:245).As such the functional results reported for these monoclonal antibodies cannot be attributed to reactivity against citrullinated proteins and/or peptides, but are due to other yet unknown mechanisms.Thus, the pathogenetic implications derived from these experiments cannot be maintained as stated.Specifically, this relates to findings presented in figure 2 A-D and 6 B-E.Note that in: Figure 2A the table ranking reactivity against citrullinated proteins and/or peptides is based on the original ELISA from the retracted Amara et al Retraction J. Exp Med 2019; 216:245; the results from this ELISA were not reproducible in other assays.In light of the lack of specificity of these monoclonal antibodies, the functional results observed in Figures 2C-D (reduction in withdrawal thresholds after injection of B02 and D10 monoclonal antibodies); 6B-C (B02/D10-induced mechanical hypersensitivity described as reduction in mechanical hypersensitivity and algesic index); and 6D-E (B02/D10-induced thermal hypersensitivity described as a change in withdrawal latency), confirming the suggested CXCL1 mediation of hypersensitivity using the CXCL1/XCL2 antagonist reparixin, cannot be attributed to reactivity against citrullinated proteins and/or peptides and must have been due to other, hitherto unknown mechanisms.Since the monoclonal antibodies were used to confirm and expand the data obtained with polyclonal antibody preparations, the remaining conclusions in the paper rely on the data from the polyclonal IgG antibodies purified by affinity chromatography on CCP2-linked Sepharose columns.Although the pronociceptive effects in mice were induced by the CCP2column eluate IgG (endotoxin free) and not the flow through fractions, also these results have to be interpreted with caution and we conclude that the pathogenetic specificity of these observations and the detailed pronociceptive mechanisms remain to be elucidated.Consequently, we feel that the title on page 730 should be corrected from "Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism" to: "Autoantibodies to citrullinated proteins may induce joint pain independent of inflammation".We specifically apologise for the delays from our side in communicating the information in this correction note to the readership of ARD.
Phase II Trial of Murine <sup>131</sup>I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas
Authors: David A. Reardon, Gamal Akabani, R. Edward Coleman, Allan H. Friedman, Henry S. Friedman, James E. Herndon, Ilkcan Cokgor, Roger E. McLendon, Charles N. Pegram, James M. Provenzale, Jennifer A. Quinn, Jeremy N. Rich, Lorna V. Regalado, John H. Sampson, Timothy D. Shafman, Carol J. Wikstrand, Terence Z. Wong, Xiao-Guang Zhao, Michael R. Zalutsky, Darell D. Bigner
Journal: Journal of Clinical Oncology (2002)

PURPOSE: To assess the efficacy and toxicity of intraresection cavity 131 I-labeled murine antitenascin monoclonal antibody 81C6 and determine its true response rate among patients with newly diagnosed malignant glioma. PATIENTS AND METHODS: In this phase II trial, 120 mCi of 131 I-labeled murine 81C6 was injected directly into the surgically created resection cavity of 33 patients with previously untreated malignant glioma (glioblastoma multiforme [GBM], n = 27; anaplastic astrocytoma, n = 4; anaplastic oligodendroglioma, n = 2). Patients then received conventional external-beam radiotherapy followed by a year of alkylator-based chemotherapy. RESULTS: Median survival for all patients and those with GBM was 86.7 and 79.4 weeks, respectively. Eleven patients remain alive at a median follow-up of 93 weeks (range, 49 to 220 weeks). Nine patients (27%) developed reversible hematologic toxicity, and histologically confirmed, treatment-related neurologic toxicity occurred in five patients (15%). One patient (3%) required reoperation for radionecrosis. CONCLUSION: Median survival achieved with 131 I-labeled 81C6 exceeds that of historical controls treated with conventional radiotherapy and chemotherapy, even after accounting for established prognostic factors including age and Karnofsky performance status. The median survival achieved with 131 I-labeled 81C6 compares favorably with either 125 I interstitial brachy-therapy or stereotactic radiosurgery and is associated with a significantly lower rate of reoperation for radionecrosis. Our results confirm the efficacy of 131 I-labeled 81C6 for patients with newly diagnosed malignant glioma and suggest that a randomized phase III study is indicated.
Correction: Cervical intraepithelial neoplasia in women with renal allografts
Authors: J Gruzelier, D Orton
Journal: BMJ (1989)

the morning immediately after night duty, rather than later in the afternoon after 31 continuous hours on duty, as we did.This is surely where the moral lies when it comes to considering the implications of our study for clinical practice.It is the long hours of continuous work rather than sleep loss that is the main culprit.
Deletion of integrated hepatitis B virus genome and cellular flanking sequences in hepatocellular carcinoma cells in BALB/c Mice
Authors: Poa-Chun Chang, Cheng-Po Hu, Shu-Hsia Chen, Sheng Wang-Wuu, Chungming Chang
Journal: Hepatology (1995)

We have previously reported the establishment of well-differentiated BALB/c mouse liver (ML) cell lines. Transfection of these cell lines with hepatitis B virus (HBV) DNA led to the expression of HBV-specific antigens and integration of HBV sequences in the cellular genome. Two cloned HBV-transfected ML cell lines, ML-2(HBV) and ML-3(HBV), expressed viral antigens and were highly tumorigenic in nude mice. However, the tumorigenicity of the two cell lines was significantly reduced in BALB/c mice. Southern blot analyses showed that the integrated HBV sequences were retained in tumors growing in nude mice but deleted in tumors growing in BALB/c mice. Furthermore, the deletion of HBV DNA was accompanied by deletion of chromosomal sequences flanking the HBV integration sites. In ML-2(HBV) cells, a significant reduction in chromosomal number was also observed. These results suggest that the immune response of BALB/c mice selected against hepatocellular carcinoma (HCC) cells expressing viral antigens and led to the proliferation of cells with deleted HBV sequences and concomitant chromosome aberrations. By using this mechanism, HCC cells escape the immune surveillance and gain the advantage of cell growth.
Evolocumab (Repatha)—A Second PCSK9 Inhibitor to Lower LDL-Cholesterol
Journal: JAMA (2015)

The second FDA-approved PCSK9 inhibitor evolocumab (Repatha) appears to be similar in efficacy and safety to alirocumab (Praluent), but no comparative studies are available. Given by subcutaneous injection every 2 weeks or once monthly, evolocumab can further lower LDL-cholesterol levels by about 60% in patients at high risk for atherosclerotic cardiovascular disease already taking maximal statin therapy. Its effect on cardiovascular outcomes remains to be established. The long-term efficacy and safety of both evolocumab and alirocumab are unknown, and they are expensive.
Error in SI Conversion Factor
Authors: Pelle Lindqvist, Charlotte Hellsten
Journal: JAMA Internal Medicine (2016)

limit of input earlier for receiving information and were "blocked" after this, or when their informational limit is reached, the information is not recorded in their memory.These women need another pathway for information absorption in addition to oral communication from a health care provider.Some possibilities include having a close relative present at information, having extra counselling, or being presented with written information.We found, however, that the exact wording of the written information was of major importance. 4 A 2-question screening as suggested by Dr Whooley 1 might aid in identifying women at risk, especially in a common highrisk situation such as confronting abnormal Papanicolau smear results.This might reduce patient stress level, increase the quality of life, and offer an understanding why information was not retained.
Ultrastructure of Heart Muscle
Authors: Joachim R. Sommer, R. A. Waugh
Journal: Environmental Health Perspectives (1978)

The ultrastructure of cardiac muscle is described. In the course of the descriptions advantage has been taken of comparative anatomy, in order to elucidate the relationships between structure and function. Physiologic parameters are discussed in a comparative manner including information from skeletal muscles fibers that often provide a well-studied point of departure. The descriptions of the ultrastructure of cardiac muscle are illustrated by a few electron photomicrographs to give a general overview.
Prognostic factors for survival in adult patients with recurrent glioma enrolled on New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium phase I and II clinical trials
Authors: K. Carson, S. A. Grossman, J. D. Fisher, E. Shaw
Journal: Journal of Clinical Oncology (2005)

1509 Background: Prognostic factor analyses have proven useful in predicting outcome in patients (pts) with newly diagnosed malignant glioma. Similar analysis should be of benefit in recurrent glioma. Methods: Between 1995 and 2002, 333 adult pts were enrolled on 10 phase I or II clinical trials of systemic or local chemotherapy or brachytherapy for the treatment of recurrent glioma. The studies had similar inclusion criteria and were conducted within the NABTT Consortium. Survival time was calculated from start of treatment until death or last follow-up. 308 (93%) pts have died. Univariate Cox proportional hazards (PH) regression analysis was performed to identify possible prognostic factors associated with an increased risk of death. Significant univariate predictors were included in multivariate analysis. Recursive partitioning analysis (RPA) was performed, and the log-rank test was used to group RPA classes with similar Kaplan-Meier survival estimates (KM). Results: Factors associated with an increased risk of death on univariate PH were increased age, lower KPS, initial and on-study histologies of GBM, steroid use, shorter time from original diagnosis to recurrence, and tumor location other than frontal. Factors that were not significant included gender, race, number of prior therapies, and anticonvulsant use. The final multivariate PH model included initial histology of GBM (relative risk (RR) = 2.04; 95% confidence interval (CI) = 1.49, 2.79), KPS < 90 (RR=1.35, 95% CI = 1.03, 1.77), 10 year increase in age (RR=1.20, 95% CI=1.06, 1.35), and steroid use (RR=1.56, 95% CI = 1.16, 2.10). RPA resulted in 5 classes, but 3 had similar KM and were combined. Median survival was poorest in GBM pts, age ≥ 50, on steroids (4.7 months (m); 95% CI=3.5, 5.3), best in pts with initial histology other than GBM and KPS ≥ 90 (20.2 m; 95% CI=12.2, 30.3), and was 7.4 m (95% CI=6.3, 9.0) for all other pts. Conclusions: Initial histology, KPS, age, and steroid use, are predictive of survival in recurrent glioma pts. Phase II and III clinical trials in pts with recurrent glioma should stratify by or adjust for these factors. No significant financial relationships to disclose.
PROGNOSIS.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
MEMBERSHIP IN THE ASSOCIATION.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE UNPREDICTABLE FATTY TUMOR
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal